Main content

    Pancreatic Cancer Clinical Research

    CPMC Cancer Services

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov


    Metastatic Pancreatic Cancer  |  Non-Metastatic Pancreatic Cancer  |  Pancreatic Neuroendocrine Tumors


    Active Trials

    Metastatic Pancreatic Cancer

    Title: A Multicenter Phase I/II Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel With or Without NPC-1C in Patients With Metastatic or Locally Advanced Pancreatic Cancer Previously Treated With FOLFIRINOX
    Description: This is a randomized phase II multi-institution prospective open label study in which up to 90 subjects with metastatic, locally advanced unresectable or recurrent pancreatic cancer who previously received treatment with chemotherapy with FOLFIRINOX or FOLFIRINOX-like regimen
    Investigator: Stephanie Jeske, MD
    Eligibility: Subjects 18 y/o and older, with recurrent, locally advanced unresectable or metastatic adenocarcinoma of the pancreas who have progressed after primary therapy with FOLFIRINOX or FOLFIRINOX-like regimen or were intolerant of it
    Status: Active and open to enrollment
    Contact: Laurel Brechtel, 415-600-1654, Email: BrechtLA@cpmcri.org about Study PB1201

    Title: A Randomized, Double-Blind, Phase 3 Study of the Janus Kinase (JAK) 1/2 Inhibitor, Ruxolitinib, or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy
    Description: To determine the efficacy, based upon overall survival, of ruxolitinib added to capecitabine for the treatment of advanced or metastatic pancreatic cancer
    Investigator: Ari Baron, MD
    Eligibility: Subjects 18 y/o and older, who have histologically or cytologically confirmed adenocarcinoma of the pancreas
    Status: Active and open to enrollment
    Contact: Laurel Brechtel, 415-600-1654, Email: BrechtLA@cpmcri.org about Study JANUS 1

    Title: A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase)Combined With Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Previously Untreated Pancreatic Cancer
    Description: PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Untreated Pancreatic Cancer (HALO-109-202)
    Investigator: Ari Baron, MD
    Eligibility: Subjects 18 y/o and older, who have histologically confirmed Stage IV pancreatic ductal adenocarcinoma w/ documented disseminated neoplasm to liver and /or lung. Must have archival or fresh tissue (block /slides) available pre-dose
    Status: Active and open to enrollment
    Contact: Laurel Brechtel, 415-600-1654, Email: BrechtLA@cpmcri.org about Study HALO-109-202

    Title: S1313, A Phase IB/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) Versus Modified FOLFIRINOX Alone in Patients With Good Performance Status Metastatic Pancreatic Adenocarcinoma
    Description: This partially randomized phase I/II trial studies the side effects and best dose of pegylated recombinant human hyaluronidase (PEGPH20) when given together with combination chemotherapy and to see how well they work compared with combination chemotherapy alone in treating patients with newly diagnosed pancreatic cancer that has spread to other places in the body
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects 18 to 75 y/o. Patients must have newly diagnosed, untreated metastatic histologically or cytologically documented pancreatic adenocarcinoma; patients must not have known history of brain metastases
    Status: Please contact site for study status
    Contact: Laurel Brechtel, 415-600-1654, Email: BrechtLA@cpmcri.org about Study SWOG 1313

    Back to top

    Active Trials

    Non-Metastatic Pancreatic Cancer

    Title: A Phase III Study of FOLFIRINOX With or Without HyperAcute®-Pancreas (Algenpantucel-L) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
    Description: Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
    Investigator: Ari Baron, MD
    Eligibility: Subjects 18 y/o and older with a diagnosis of pancreatic cancer
    Status: Active and open to enrollment
    Contact: Laurel Brechtel, 415-600-1654, Email: BrechtLA@cpmcri.org about Study NLG0505

    Back to top

    Active Trials

    Pancreatic Neuroendocrine Tumors

    Title: A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors
    Description: This randomized phase II trial studies how well giving temozolomide with or without capecitabine works in treating patients with advanced pancreatic neuroendocrine tumors
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects 18 y/o and older, who have histologically or pathologically confirmed locally unresectable or metastatic low or intermediate grade pancreatic neuroendocrine tumor, excluding small cell carcinoma
    Status: Please contact site for study status
    Contact: Laurel Brechtel, 415-600-1654, Email: BrechtLA@cpmcri.org about Study ECOG E2211

    • updated August 2015

    Back to top